Ocular Therapeutix, Inc.
(NASDAQ:OCUL) stock is trading higher on Wednesday as the company prepares for its Investor Day, where it will detail its plans for submitting a New Drug Application (NDA) for AXPAXLI.
The stock's decline comes amid a mixed market backdrop, with S&P 500 futures showing a slight gain of 0.1%.
OCUL Investor Day: AXPAXLI NDA Submission Plan And FDA Alignment The eye-focused biotech plans to submit an NDA for AXPAXLI in wet age-related macular degeneration (AMD) during the fourth quarter of 2026 after reaching alignment with the U.S.
Food and Drug Administration (FDA) on a filing strategy centered on data from the SOL-1 trial.
